Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned subsidiary of Bayer AG, was granted Fast Track Designation from the U.S. FDA for the LION-101 gene therapy program. LION-101 is a novel recombinant adeno-associated virus (rAAV) based vector being developed as a one-time intravenous infusion for the treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9).   The FDA recently cleared an Investigational New Drug (IND) application for LION-101, to authorize the start of a Phase ...